Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Current Professional Summary
The ultimate goal of my past training and current efforts is to engage the difficult clinical problem of HCV infection, particularly in special populations. Special populations include those with HIV-1/HCV coinfection, acute HCV, and HCV in the prison population. The overall focus of my research is on HCV and HIV translational research at the Division of Infectious Diseases at Massachusetts General Hospital, including multiple projects in immunogenetics and immunology of HCV infection and acute HCV in Massachusetts both in the community and in the prison population. I direct the Viral Hepatitis Clinic in the Division of Infectious Diseases at the Massachusetts General Hospital and am actively involved in the care and treatment of those living with HBV and HCV. I am currently serving as IDSA co-chair of the AASLD/IDSA HCV guidance available at http://hcvguidelines.org.
Committees and Organizations
- Member, AIDS Clinical Trial Group, Hepatitis Transformative Science Group
- Co-chair, AASLD / IDSA HCV guidance available at http://hcvguidelines.org
Honors and Awards
- Maxwell Finland Award for Research Excellence, Massachusetts Infectious Disease Society
- Fellow, Infectious Disease Society of America
- Yale University, B.S. 1993
- Harvard Medical School, M.D. 1997
- Kim AY, Lauer GM, Ouchi K, Addo MM, Lucas M, Schulze Zur Wiesch J, Timm J, Boczanowski M, Duncan JE, Wurcel AG, Casson D, Chung RT, Draenert R, Klenerman P, Walker BD. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T cell count in HIV-1 coinfected individuals. Blood. 2005; Feb 1:105(3): 1170-8. PMID:15459014.
- Kim AY, Schulze zur Wiesch J, Kuntzen T, Timm J, Kaufmann DE, Duncan JE, Jones AM, Wurcel AG, Davis BT, Gandhi RT, Robbins GK, Allen TM, Chung RT, Lauer GM, Walker BD. Impaired HCV-specific T cell responses and recurrent HCV in HIV coinfection. PLoS Med 2006 Dec;3(12):e492. PMC1705826.
- Kim AY, Timm J, Nolan BE, Reyor LL, Kane K, Berical AC, Zachary KC, Lauer GM, Kuntzen T, Allen TM. Temporal dynamics of a predominant protease-inhibitor resistance mutation in a treatment naïve HCV-infected individual. Journal of Infectious Diseases. 2009;199(5):737-41. PMC2653266 4.
- Chen TY, Ding EL, Seage GR, Kim AY. Meta-analysis: increased mortality associated with HCV in HIV-infected persons is not related to HIV disease progression. Clinical Infectious Diseases. 2009;49(10):1605-15. PMC2805261.
- Kim AY and Chung RT. Coinfection with HIV-1 and HCV – a one-two punch. Gastroenterology 2009;137(3):795-814.
- Mcgovern BH, Nagami EH, Birch CE, Bowen MJ, Reyor LL, Chung RT, Kim AY. Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection. Journal of Infectious Diseases. 2009;200(6):877-81. PMC2762747 7.
- Mcgovern BH, Birch CE, Bowen MJ, Reyor LL, Nagami EH, Chung RT, Kim AY. Improving the diagnosis of acute hepatitis C infection using expanded viral load criteria. Clinical Infectious Diseases. 2009;49(7):1051-60. PMC2741541.
- Kim AY, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyor LL, Berical AC, Feller AJ, Johnson KL, Schulze zur Wiesch J, Robbins GK, Chung RT, Walker BD, Carrington M, Allen TM, Lauer GM. Spontaneous control of HCV is associated with the expression of HLA-B*57 and preservation of targeted epitopes. Gastroenterology 2011; 140(2):686-696. PMC3021586 9.
- Schulze zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprowicz V, Nolan BE, Streeck H, Aneja J, Reyor LL, Allen TM, Lohse AW, McGovern B, Chung RT, Kwok WW, Kim AY, Lauer GM. Broadly directed CD4+ responses are primed during acute HCV infection, but rapidly disappear from the blood with viral persistence. J Exp Med2012;209(1):61-75. 5.
- Kim AY, Nagami EH, Birch CE, Bowen MJ, Lauer GM, McGovern BH. A simple strategy to identify acute HCV infection among newly incarcerated injection drug users. Hepatology 2013;57(3):944-52. PMID:23111904.
- Onofrey S, Aneja J, Haney GA, Nagami EH, DeMaria Jr A, Lauer GM, Hills-Evans K, Barton K, Kulaga S, Bowen MJ, Cocoros N, McGovern BH, Church DR, Kim AY. Underascertainment of Acute Hepatitis C Infections in the U.S. Surveillance System: A Case Series and Chart Review. Annals of Internal Medicine 2015; 163(4):254-61. PMID: 26121304
- Kim A. Hepatitis C Virus. Ann Intern Med. 2016 Sep 6;165(5):ITC33-ITC48. doi: 10.7326/AITC201609060. Review. PubMed PMID: 27595226.
- Linas BP, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY. Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. Open Forum Infect Dis. 2016 Dec 27;4(1):ofw266. doi: 10.1093/ofid/ofw266. eCollection 2017 Winter. PubMed PMID: 28480259; PubMed Central PMCID: PMC5414108.